PRAME_Prame Activators
PRAME (Preferentially Expressed Antigen in Melanoma) activators are a class of compounds that focus on modulating the expression and function of the PRAME protein. PRAME is a member of the cancer-testis antigen family, known for its expression in various types of cancer cells while being restricted in normal adult tissues. The biological role of PRAME is complex and involves its participation in transcriptional regulation, where it can act as a repressor of retinoic acid receptor (RAR) signaling pathways. This signaling pathway is involved in cell differentiation and proliferation. PRAME activators, therefore, are chemicals that can increase the expression or enhance the function of PRAME, influencing the pathways it regulates.
The mechanism of action of PRAME activators may vary depending on the specific compound. Some activators might directly bind to the PRAME protein, inducing a conformational change that increases its stability or its affinity for other regulatory components within the cell. Other activators may increase the transcriptional levels of PRAME, either by interacting with promoter regions of the PRAME gene or by modulating the activity of transcription factors that drive PRAME expression. Additionally, PRAME activators might work indirectly by inhibiting negative regulators of PRAME or by altering signaling pathways that affect PRAME's activity. By increasing the functional activity of PRAME, these activators can have a significant impact on the cellular processes controlled by the RAR signaling pathway, which includes the regulation of genes involved in cell differentiation and proliferation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
ATRA, involved in cell differentiation and apoptosis, might indirectly influence PRAME by affecting differentiation pathways in cancer cells. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Decitabine, a DNA methyltransferase inhibitor, may affect PRAME expression indirectly by altering DNA methylation patterns in cancer cells. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
Azacitidine, another DNA methyltransferase inhibitor, could potentially modulate PRAME activity through epigenetic modifications. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
5-Fluorouracil, a chemotherapeutic agent, might influence PRAME activity indirectly through its effects on DNA synthesis and repair in cancer cells. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
HDAC inhibitors can affect chromatin structure and gene expression, potentially modulating PRAME activity indirectly. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
These inhibitors can modulate signaling pathways crucial for cancer cell growth and survival, potentially affecting PRAME activity. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
In melanoma with BRAF mutations, BRAF inhibitors may indirectly influence PRAME expression and activity in the tumor microenvironment. | ||||||